Study suggests LAM is more prevalent than previously thought
“Rare diseases are often disregarded given their rarity. Most are underdiagnosed. The minute you tell clinicians that this is actually four to five times more
A Conversation with Vera Krymskaya, PhD, MBA, Scientific Director
Dr. Vera Krymskaya has been appointed Scientific Director at The LAM Foundation after serving as interim since July 2023. She is the first female PhD
LAM Patient Research Priorities Survey Opens in March 2024
Dear LAM Community Members, The LAM Foundation prioritizes supporting LAM scientific research, funding a wide range of projects and initiatives. To maximize impact for LAM
The Latest in LAM Science: Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
The mTORC1 pathway is a signaling pathway in cells in the body that controls cell growth and survival. In many cancers and in LAM, this
The Latest in LAM Science: Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis
LAM is caused by changes in some genes that control cell growth called the mTORC1 pathway. Cells use this pathway to make many copies of
This is Where Hope Lives
Google told me I had ten years to live. Ten years. Isaiah turned 10 this year, and he’s only just begun to live a life.
The LAM Foundation Announces Interim Executive Director
On behalf of the Board of Directors of The LAM Foundation, I am thrilled to announce the arrival of Dr. Patricia A. Gentile, Ed.D, as
Statement on Pfizer’s decision on the brand drug, Rapamune, in the U.S.
The LAM Foundation was made aware just yesterday by Pfizer that they will no longer sell or have availability of their brand drug, RAPAMUNE® in
Leadership Change at The LAM Foundation
After a decade of remarkable leadership of the LAM Foundation, Sue Sherman has informed the Board of Directors of her decision to step down from
Report: Exercise with LAM is Safe and Effective
A question that comes up frequently within the LAM community is whether exercise can improve life for individuals with LAM – and if so, how
COVID-19 continues to persist in the community at a relatively low level, mainly in the form of Omicron subvariants. Omicron subvariants are highly transmissible but
The latest in LAM research
Although the FDA’s approval of sirolimus for lymphangioleiomyomatosis was a major breakthrough in treating the disease, the drug does not work for all LAM patients.